Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H1 2018
SUMMARY
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 37 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Friedreich Ataxia, Psoriasis, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Chronic Kidney Disease (Chronic Renal Failure), Mitochondrial Diseases, Parkinson's Disease, Pulmonary Arterial Hypertension, Retinal Degeneration, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Aspiration Pneumonitis, Asthma, Atherosclerosis, Autism, Brain Ischemia, Breast Cancer, Cardiomyopathy, Cardiovascular Disease, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Diabetic Complications, Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Glomerulonephritis, Huntington Disease, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Ischemic Stroke, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Proteinuria, Pulmonary Hypertension, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Radiodermatitis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 37 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.
The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 3, 4, 15 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Metabolic Disorders, Cardiovascular, Respiratory, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Inflammation, Multiple Sclerosis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Friedreich Ataxia, Psoriasis, Type 2 Diabetes, Amyotrophic Lateral Sclerosis, Chronic Kidney Disease (Chronic Renal Failure), Mitochondrial Diseases, Parkinson's Disease, Pulmonary Arterial Hypertension, Retinal Degeneration, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Age Related Macular Degeneration, AIDS Associated Dementia, Alport Syndrome, Alzheimer's Disease, Aspiration Pneumonitis, Asthma, Atherosclerosis, Autism, Brain Ischemia, Breast Cancer, Cardiomyopathy, Cardiovascular Disease, Cerebral Vasospasm, Chagas Disease (American Trypanosomiasis), Diabetic Complications, Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Glomerulonephritis, Huntington Disease, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Ischemia Reperfusion Injury, Ischemic Stroke, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis, Osteoporosis, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Proteinuria, Pulmonary Hypertension, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Radiodermatitis, Relapsing Remitting Multiple Sclerosis (RRMS), Retinopathy, Subarachnoid Hemorrhage and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development
Arbor Pharmaceuticals LLC
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings PLC
Catabasis Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
vTv Therapeutics Inc
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles
(alpha lipoic acid + losartan potassium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DH-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LGM-2605 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-526 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIND-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
monosodium luminol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-970 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTI-79 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target NRF2 and BACH1 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NFE2L2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NRF-2 for COPD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUL-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBE-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tepilamide fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFM-735 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEDA-1209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Reata Announces That Kyowa Hakko Kirin Initiated AYAME, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease
May 31, 2018: Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Diabetic Kidney Disease
May 31, 2018: Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome
May 25, 2018: Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
May 02, 2018: Evgen Pharma: Grant of further European patent
Apr 24, 2018: Evgen Pharma Announces Presentation at World Orphan Drug Congress USA
Apr 24, 2018: Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
Apr 11, 2018: Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
Mar 29, 2018: Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
Mar 28, 2018: Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare
Mar 22, 2018: Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
Mar 06, 2018: V ClinBio Partners with Camargo for Strategic 505(b)(2) Development of Multiple Sclerosis Drug Candidate CLX-106
Mar 05, 2018: Evgen Pharma: Update on novel sulforaphane analogues
Mar 01, 2018: Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Overview
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Companies Involved in Therapeutics Development
Arbor Pharmaceuticals LLC
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings PLC
Catabasis Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
vTv Therapeutics Inc
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Drug Profiles
(alpha lipoic acid + losartan potassium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-1521 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bardoxolone methyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DH-404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl fumarate DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LGM-2605 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-526 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIND-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
monosodium luminol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nifurtimox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-970 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTI-79 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFX-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Nrf2 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target NRF2 and BACH1 for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 2 to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NFE2L2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate NRF-2 for COPD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Nrf2 for Oncology and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUL-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBE-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tepilamide fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TFM-735 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEDA-1209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Dormant Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Discontinued Products
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Reata Announces That Kyowa Hakko Kirin Initiated AYAME, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease
May 31, 2018: Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Diabetic Kidney Disease
May 31, 2018: Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome
May 25, 2018: Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study
May 02, 2018: Evgen Pharma: Grant of further European patent
Apr 24, 2018: Evgen Pharma Announces Presentation at World Orphan Drug Congress USA
Apr 24, 2018: Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
Apr 11, 2018: Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome
Mar 29, 2018: Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
Mar 28, 2018: Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare
Mar 22, 2018: Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
Mar 06, 2018: V ClinBio Partners with Camargo for Strategic 505(b)(2) Development of Multiple Sclerosis Drug Candidate CLX-106
Mar 05, 2018: Evgen Pharma: Update on novel sulforaphane analogues
Mar 01, 2018: Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Arbor Pharmaceuticals LLC, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by BioApex sro, H1 2018
Pipeline by Biogen Inc, H1 2018
Pipeline by C4X Discovery Holdings PLC, H1 2018
Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Evgen Pharma Plc, H1 2018
Pipeline by Ixchel Pharma LLC, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018
Pipeline by Reata Pharmaceuticals Inc, H1 2018
Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Pipeline by vTv Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1)
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Arbor Pharmaceuticals LLC, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by BioApex sro, H1 2018
Pipeline by Biogen Inc, H1 2018
Pipeline by C4X Discovery Holdings PLC, H1 2018
Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Evgen Pharma Plc, H1 2018
Pipeline by Ixchel Pharma LLC, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018
Pipeline by Reata Pharmaceuticals Inc, H1 2018
Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Pipeline by vTv Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Arbor Pharmaceuticals LLC
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings PLC
Catabasis Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
vTv Therapeutics Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Arbor Pharmaceuticals LLC
Bayer AG
BioApex sro
Biogen Inc
C4X Discovery Holdings PLC
Catabasis Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Evgen Pharma Plc
Ixchel Pharma LLC
Jiangsu Hengrui Medicine Co Ltd
Mochida Pharmaceutical Co Ltd
Reata Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
vTv Therapeutics Inc
